Evidence map›Paper›PMID 40332737›Full record

ArticleCurrent medical science2025

Vitamin D Activates Nrf2 to Prevent Nerve Injury and Reduce Brain Damage in Acute Cerebral Infarction.

Hong-Min Zhao, Li-Qin Mu, Jing Wang, Run-Zhi Chen, Yang Li, Lin Zhao, Yu Zhao, Li-Na Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Vitamin D Promotes Neuronal Survival via Nrf2 Upregulation in D-Galactose-Induced Mice: An In-Vivo and In-Silico Study.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hong-Min ZhaoDepartment of General Practice, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, China.
Li-Qin MuDepartment of General Practice, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, China.
Jing WangDepartment of General Practice, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, China.
Run-Zhi ChenDepartment of General Practice, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, China.
Yang LiDepartment of General Practice, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, China.
Lin ZhaoDepartment of General Practice, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, China.
Yu ZhaoDepartment of General Practice, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, China.
Li-Na LiuDepartment of General Practice, The First Hospital of Hebei Medical University, Shijiazhuang, 050031, China. liulina@hebmu.edu.cn.ORCID http://orcid.org/0009-0001-6946-0609

Funding

Medical Science Research Project Program of Hebei Province 20211722
6 · The paper itself

Abstract

objectiveThis study aimed to investigate the neuroprotective effects of cholecalciferol cholesterol emulsion (CCE), a vitamin D (VD) precursor, in a murine model of acute cerebral infarction (ACI) and to elucidate the role of the Nrf2 signaling pathway in mediating these effects.

methodsForty C57BL/6J mice (male and female) were divided into five groups (n = 10 per group): control, control + CCE, ACI, ACI + CCE, and ACI + CCE + ML385 (an Nrf2 inhibitor). ACI was induced by middle cerebral artery occlusion (MCAO). CCE was administered for three weeks prior to ACI induction, and ML385 was administered intravenously to inhibit Nrf2. Neurological function, brain edema, and infarct size, as well as inflammatory and apoptotic marker levels, were assessed post-ACI. Statistical analyses were conducted via one-way ANOVA and Student's t test, with P < 0.05 considered significant.

resultsCompared to ACI group, CCE significantly reduced neurological deficits, brain edema, and infarct size (P < 0.01). The ACI + CCE group presented improved short-term memory retention, as evidenced by shorter avoidance latency in shuttle avoidance tests (P < 0.01). CCE administration attenuated the expression of inflammatory markers (IL-6, MIF, Lp-PLA2) while increasing IL-10 levels (P < 0.001). Furthermore, CCE increased Nrf2 and HO-1 expression and reduced apoptosis by decreasing the Bax/Bcl-2 ratio in brain tissue (P < 0.001). ML385 abolished these neuroprotective effects, confirming the role of the Nrf2 pathway in mediating the benefits of VD.

conclusionVD, via VD receptor-mediated activation of the Nrf2/HO-1 pathway, reduces inflammation, apoptosis, and neurological damage following ACI. These findings support the therapeutic potential of VD in the treatment of ischemic stroke and highlight the importance of Nrf2 in mediating these effects.

Indexed as

Cerebral InfarctionInfarction, Middle Cerebral ArteryNeuroprotective AgentsNF-E2-Related Factor 2Vitamin DAnimalsApoptosisBrain EdemaDisease Models, AnimalFemaleMaleMiceMice, Inbred C57BLSignal TransductionNeuroprotective AgentsNfe2l2 protein, mouseNF-E2-Related Factor 2Vitamin DAcute cerebral infarctionApoptosisCholecalciferol cholesterol emulsionNeuroprotectionNrf2 signaling pathwayVitamin D

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.